1. 303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors. (September 2015) Authors: De Weger, V.; Varga, A.; De Jonge, M.; Langenberg, M.; Mergui-Roelvink, M.; Massard, C.; Van der Vlist, A.; Devriese, L.; Goodstal, S.; Zheng, W.; Tuffal, G.; Semiond, D.; Macé, S.; Watters, J.; Demers, B.; Schellens, J.; Deutsch, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma. (March 2019) Authors: de Ruiter, E.J.; Mulder, F.; Speel, E.; van den Hout, M.; de Roest, R.; Bloemena, E.; Devriese, L.; Willems, S. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗